Pharmaceutical Information |
Drug Name |
Regadenoson |
Drug ID |
BADD_D01921 |
Description |
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008. |
Indications and Usage |
Diagnostic agent for radionuclide myocardial perfusion imaging (MPI) |
Marketing Status |
approved; investigational |
ATC Code |
C01EB21 |
DrugBank ID |
DB06213
|
KEGG ID |
D05711
|
MeSH ID |
C430916
|
PubChem ID |
219024
|
TTD Drug ID |
D0XE1C
|
NDC Product Code |
55150-443; 0409-1401; 76329-3321; 42973-229; 76055-0024; 60505-6116; 72611-874; 59285-029; 69766-103; 68083-175; 16729-477; 71288-201; 0641-6253; 65129-1331; 43598-616; 0469-6501; 62147-0220; 36000-364 |
UNII |
2XLN4Y044H
|
Synonyms |
regadenoson | Lexiscan | CVT 3146 | CVT3146 | CVT-3146 |
|
Chemical Information |
Molecular Formula |
C15H18N8O5 |
CAS Registry Number |
313348-27-5 |
SMILES |
CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|